Fixed-Duration First-Line Therapy for Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) in Canada: A Canadian Expert Clinical Framework

Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is an indolent B cell malignancy that may present with lymphocytosis, lymphadenopathy, splenomegaly, cytopenias, and/or immune complications.1,2 In 2023, 2,030 people in Canada (excluding Nova Scotia) were diagnosed with CLL, resulting in an incidence rate of 5.2 per 100,000 population.3 The CLL prevalence was projected to increase from 15,512 in 2020 to 19,517 in 2025, driven by rising incidence and longer survival from treatment improvements.4 The treatment landscape for CLL/SLL has evolved substantially with the introduction of multiple targeted therapies that differ in treatment duration, toxicity profile, and logistical complexity. This article discusses the current first-line treatment of CLL/SLL in Canada, focusing on fixed-duration (FD) treatment options that combine venetoclax with obinutuzumab, acalabrutinib, or ibrutinib, and discusses their implications for individualized treatment selection, therapeutic sequencing, and real-world implementation.

Authors

Institutions

Publication Details

Journal
Canadian Hematology Today
Published
2026-11-12
DOI
https://doi.org/10.58931/cht.2026.5s0394
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Fixed-Duration First-Line Therapy for Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) in Canada: A Canadian Expert Clinical Framework

Isabelle Fleury, Alina S. Gerrie, Versha Banerji, Christopher Hillis et al.
Canadian Hematology Today
Chronic Lymphocytic Leukemia Research
article

Fixed-Duration First-Line Therapy for Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) in Canada: A Canadian Expert Clinical Framework

Isabelle Fleury, Alina S. Gerrie, Versha Banerji, Christopher Hillis, Robert Puckrin
article en

Abstract

Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is an indolent B cell malignancy that may present with lymphocytosis, lymphadenopathy, splenomegaly, cytopenias, and/or immune complications.1,2 In 2023, 2,030 people in Canada (excluding Nova Scotia) were diagnosed with CLL, resulting in an incidence rate of 5.2 per 100,000 population.3 The CLL prevalence was projected to increase from 15,512 in 2020 to 19,517 in 2025, driven by rising incidence and longer survival from treatment improvements.4 The treatment landscape for CLL/SLL has evolved substantially with the introduction of multiple targeted therapies that differ in treatment duration, toxicity profile, and logistical complexity. This article discusses the current first-line treatment of CLL/SLL in Canada, focusing on fixed-duration (FD) treatment options that combine venetoclax with obinutuzumab, acalabrutinib, or ibrutinib, and discusses their implications for individualized treatment selection, therapeutic sequencing, and real-world implementation.

Canadian Hematology Today
University of British Columbia (CA), University of Calgary (CA), Juravinski Cancer Centre (CA), McMaster University Medical Centre (CA), Juravinski Hospital (CA), Université Laval (CA), University of Manitoba (CA), Hamilton Health Sciences (CA)
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon